I-STAT CREA CARTRIDGE
Received Oct 10, 2017 · Event occurred Aug 30, 2016
Report 2245578-2017-00488 · MDR key 6939424
Device
Generic name
Crea Cartridge
Manufacturer
Abbott Point Of CareModel number
NACatalog number
03P84-25
Lot number
A16128
Product problems
- Incorrect, Inadequate or Imprecise Result or Readings
- Incorrect, Inadequate or Imprecise Result or Readings
Patient
72 YR
- No Code Available
- No Code Available
Narrative
Additional Manufacturer Narrative
APOC INCIDENT # (B)(4). APOC LABELING WAS EVALUATED DURING THE INVESTIGATION AS PERTAINING TO THE EVENT. THE INVESTIGATION WAS COMPLETED ON 11/09/2016. RETAIN PRODUCT WAS TESTED AND FUNCTIONING ACCORDING TO SPECIFICATION. RETURN PRODUCT IS NOT AVAILABLE FOR INVESTIGATION. INVESTIGATION: A REVIEW OF THE DEVICE HISTORY RECORD (DHR) CONFIRMED THAT THE CARTRIDGE LOT MET FINISHED GOODS (FG) RELEASE CRITERIA. RETAINED TEST DATA MET THE ACCEPTANCE CRITERIA OUTLINED IN APPENDIX 1 OF Q04.01.003 REV. Z (PRODUCT COMPLAINT LEVEL 2 AND LEVEL 3 INVESTIGATION PROCEDURE). NO DEFICIENCY WAS IDENTIFIED. ASSESSMENT: NO REPEATS ON THE I-STAT OR THE LABORATORY. TWO DIFFERENT SAMPLES TESTED. THE COMPLAINT INVESTIGATION CONCLUDED THERE WAS NO PRODUCT DEFICIENCY AND THAT THE I-STAT CARTRIDGE LOT IS MEETING SPECIFICATION.
Description of Event or Problem
ON (B)(6) 2016, ABBOTT POINT OF CARE WAS CONTACTED BY A CUSTOMER REGARDING I-STAT CREA CARTRIDGES THAT YIELDED SUSPECTED DISCREPANT CREATININE RESULT ON A (B)(6) YEAR OLD MALE PATIENT PRESENTED TO THE EMERGENCY ROOM FOR A COUGH . CREATININE WAS TESTED TO DETERMINE IF CONTRACT SHOULD BE GIVEN BEFORE IMAGING. THERE WERE NO INJURIES ASSOCIATED WITH THIS EVENT, THE PATIENT WAS TREATED BASED ON THE LAB RESULTS. THERE WAS NO REPEAT ON I-STAT. THERE WAS NO ADDITIONAL PATIENT INFORMATION AVAILABLE AT THE TIME OF THIS REPORT. RETURN PRODUCT IS NOT AVAILABLE FOR INVESTIGATION. I-STAT, 1.7, RESULTED AT 12:51, COBAS 0.8, COLLECTED AT 13:31, RESULTED A APPROXIMATELY 13:50 . AT THE TIME OF THE EVENT THERE WAS NO INDICATION OF A PRODUCT MALFUNCTION BASED ON THE INFORMATION PROVIDED AND ASSESSED BY APOC, HOWEVER THIS MDR IS A RETROSPECTIVE FILING IN RESPONSE TO AN OBSERVATION FROM AN FDA INSPECTION CONDUCTED MAY 8TH TO 12TH, 2017 AT ABBOTT POINT OF CARE (B)(4).